Scarica l'app Stockscreener
113.90
1.15%
-1.32
Dopo l'orario di chiusura:
114.18
0.28
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$115.22
Aprire:
$115.36
Volume 24 ore:
1.96M
Relative Volume:
0.92
Capitalizzazione di mercato:
$12.93B
Reddito:
$1.51B
Utile/perdita netta:
$348.84M
Rapporto P/E:
40.96
EPS:
2.7805
Flusso di cassa netto:
$667.65M
1 W Prestazione:
+1.29%
1M Prestazione:
+4.19%
6M Prestazione:
+80.11%
1 anno Prestazione:
+53.98%
Intervallo 1D:
$113.43
$115.62
Intervallo di 1 settimana:
$110.95
$116.84
Portata 52W:
$61.23
$116.84
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
113.90 | 12.93B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Downgrade | Goldman | Neutral → Sell |
| 2025-10-14 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance UK
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo! Finance Canada
Halozyme stock falls 2.34% after strong quarterly growth - AD HOC NEWS
$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? - Yahoo Finance
Form 8K Halozyme Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Halozyme Therapeutics completes $1.5 billion convertible notes offering By Investing.com - Investing.com Canada
Halozyme Therapeutics completes $1.5 billion convertible notes offering - Investing.com
Halozyme Therapeutics Raises $1.5 Billion in 1.50% Convertible Notes, Adds Capped Calls - TradingView
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - sg.finance.yahoo.com
Halozyme Therapeutics stock rises as $1.3 billion convertible notes fuel growth guidance - AD HOC NEWS
Halozyme (HALO) Just Made A $1.3B Bet On Itself - Yahoo Finance
Latham & Watkins Advises on Halozyme Therapeutics, Inc.’s Upsized US$1.3 Billion Convertible Senior Notes Offering - Latham & Watkins LLP
(HALO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost? - Yahoo Finance
Halozyme Therapeutics stock edges higher as investors weigh Q2 growth and pipeline risk - AD HOC NEWS
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - easternprogress.com
Is Halozyme Therapeutics (HALO) Fully Valued As Growth Calls And Partnerships Draw Fresh Attention? - webull.com
Halozyme Therapeutics Prices $1.3 Billion Convertible Senior Notes with Additional $200 Million Overallotment Option - Kalkine Media
Dynatrace, Cava Group, Halozyme Therapeutics - TradingView
Halozyme Therapeutics, Etsy, Netflix - TradingView
Halozyme Therapeutics stock hits all-time high at 111.56 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics stock hits all-time high at 111.56 USD - Investing.com
Halozyme prices $1.3B of 1.50% convertible notes due 2033, upsized with $200M option - TradingView
Halozyme Prices $1.3 Billion Convertible Senior Notes Offering - marketscreener.com
HALO Looks 10.2% Overvalued on GF Value™ - GuruFocus
Halozyme prices $1.3B convertible notes to fund repurchases and growth initiatives - Pluang
Halozyme prices $1.3 billion convertible notes offering - Investing.com
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - prnewswire.com
HALOZYME THERAPEUTICS (NASDAQ: HALO) Announces $1.05 Billion Convertible Senior Notes Offering with $150 Million Option - Kalkine Media
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Prices Upsized $1.3B 1.50% Convertible Notes Due 2033 - TradingView
Halozyme Therapeutics Plans $1.05 Billion Offering of Convertible Notes - marketscreener.com
Halozyme Therapeutics plans a $1.05B convertible notes sale - TradingView
Years of RSU awards set for sale by Halozyme (NASDAQ: HALO) director - stocktitan.net
Halozyme plans $1.05 billion convertible notes offering - Investing.com
Halozyme proposes $1.05B convertible notes due 2033, with $150M option - TradingView
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Plans $1.05B Convertible Notes Due 2033 - TradingView
Is Halozyme Therapeutics (HALO) Fully Priced Ahead Of Its September Conference Run? - Yahoo Finance
Halozyme Therapeutics, Inc. at HC Wainwright Global Investment Conference Transcript - GuruFocus
Zacks.com featured highlights include Halozyme Therapeutics, Avnet, BILL and Venture Global - Yahoo Finance
Halozyme Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Halozyme president and CEO Helen Torley sells $6.4 million in stock By Investing.com - Investing.com South Africa
Halozyme president and CEO Helen Torley sells $6.4 million in stock - Investing.com Australia
Halozyme (NASDAQ: HALO) CEO exercises options, sells 60,000 shares - Stock Titan
Halozyme Therapeutics(HALO.US) Officer Sells US$6.44 Million in Common Stock - Moomoo
Record Revenue Growth Boosts Halozyme Shares - FXEmpire
Why (HALO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Alteogen Licenses ALT-B4 to Novartis in Deal Worth Up to $3.2 Billion, Reaffirming Value of SC Formulation Platform - finance.biggo.com
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):